Skip to Main Content

Amid ongoing debate over the effect of the recent tax law, one lawmaker complains that shareholders in the nation’s 10 largest drug makers will reap a “windfall,” but the average American will not share in the bounty because none of these companies is using tax cuts to lower prescription medicine prices.

In a new report, Sen. Cory Booker (D-N.J.) noted that several of the companies have announced more than $45 billion in stock buybacks, but overall, there has been only “limited mention” of investments in ways that could benefit patients and workers, such as increases in R&D and capital investment for building new facilities and creating jobs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED